Introduction
Nephrotic syndrome is commonly seen in nephrology clinics in both developed and developing countries, although the prevalence in the general population is estimated to be only 16 cases per 100,000 children. 1 About 80% of paediatric cases of nephrotic syndrome in the Western hemisphere are steroid-sensitive nephrotic syndrome (SSNS); steroid-resistant nephrotic syndrome (SRNS) accounts for about 20% of cases.
1,2 SRNS variants are often caused by focal segmental glomerulosclerosis (FSGS) and are commonly characterized by rapid progression to end-stage renal disease (ESRD), requiring dialysis and kidney transplantation within 2-10 years of diagnosis.
The pathogenesis of nephrotic syndrome has not been clearly delineated. However, a landmark study by the Tryggvason group in 1998 identified mutations in nephrin (NPHS1), an essential component of the podocyte slit diaphragm, as a cause of congenital nephrotic syndrome. 3 This finding demonstrated the importance of the podocyte in the pathogenesis of nephrotic syndrome, and led to the proposal that most cases of nephrotic syndrome are caused by podocyte defects, and should therefore be classified as 'podocytopathies' . 4 Since the discovery that nephrin mutations can cause nephrotic syndrome, several studies have reported mutations in other genes in both paediatric and adult-onset nephrotic syndrome. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Of note, most of the genes identified to date are localized to the podocyte or the slit diaphragm, which confirms the importance of podocyte dysfunction in the pathogenesis of nephrotic syndrome. A rare exception is LAMB2, the protein product of which is enriched in the glomerular basement membrane. 8 The genes associated with auto somal recessive and autosomal dominant nephrotic syndrome identified to date and the phenotypes associated with each of these genes are presented (Tables 1 and 2 ). The most prevalent autosomal recessive genes and autosomal dominant genes are listed in Box 1. Despite the discovery of all of these genes, no large-scale population studies have delineated the burden of disease caused by monogenic nephrotic syndrome. Nevertheless, extrapolation from selected adult case series seems to suggest that <10% of all cases of SRNS due to FSGS, and <2% of all cases of nephrotic syndrome, are probably a result of single gene defects. 22 This finding raises questions about the clinical utility, relevance, and cost-effectiveness of large-scale genetic testing in patients presenting with nephrotic syndrome.
Clear guidelines for genetic testing need to be developed for both clinicians and research ers, and continued dialogue is needed on the challenges posed by judicious clinical utilization of the information from both positive and negative genetic tests. This manuscript articulates our collective opinion on the clinical indications for genetic testing in nephrotic syndrome and the clinical utility of genetic testing in monogenic nephrotic syndrome based on the evidence available to date. We will focus on single gene defects, as complex inheritance issues are beyond the scope of this article.
Genetics of nephrotic syndrome
Monogenic nephrotic syndrome (that is, nephrotic syndrome caused by a single gene defect) can be inherited as an autosomal recessive or autosomal dominant condition, and can either be isolated or be part of a multi systemic inherited disorder.
OPINION
Genetic testing in nephrotic syndrome -challenges and opportunities
Rasheed A. Gbadegesin, Michelle P. Winn and William E. Smoyer
Abstract | Monogenic nephrotic syndrome (nephrotic syndrome caused by a single gene defect) is responsible for only a small percentage of cases of nephrotic syndrome, but information from studies of the unique cohort of patients with this form of the disease has dramatically improved our understanding of the disease pathogenesis. The use of genetic testing in the management of children and adults with nephrotic syndrome poses unique challenges for clinicians in terms of who to test and how to use the information obtained from testing in the clinical setting. In our view, not enough data exist at present to justify the routine genetic testing of all patients with nephrotic syndrome. Testing is warranted, however, in patients with congenital nephrotic syndrome (onset at 0-3 months), infantile nephrotic syndrome (onset at 3-12 months), a family history of nephrotic syndrome, and those in whom nephrotic syndrome is associated with other congenital malformations. The family and/or the patient should be given complete and unbiased information on the potential benefits and risks associated with therapy, including the reported outcomes of treatment in patients with similar mutations. Based on the data available in the literature so far, intensive immunosuppressive treatment is probably not indicated in monogenic nephrotic syndrome if complete or partial remission has not been achieved within 6 weeks of starting treatment. We advocate that family members of individuals with genetic forms of nephrotic syndrome undergo routine genetic testing prior to living-related kidney transplantation. Prospective, multicentre studies are needed to more completely determine the burden of disease caused by monogenic nephrotic syndrome, and randomized controlled trials are needed to clarify the presence or absence of clinical responses of monogenic nephrotic syndrome to available therapies.
The major causes of autosomal recessive nephrotic syndrome are mutations in nephrin (NPHS1), podocin (NPHS2), and phospholipase C epsilon 1 (PLCE1) (Box 1). Indeed, two large cohort studies of children with hereditary nephrotic syndrome reported that mutations in NPHS2 were present in 18-26% of cases. 23, 24 In a similar study limited to children with nephrotic syndrome manifesting in the first year of life, Hinkes et al. reported that mutations in NPHS1 and NPHS2 were responsible for 60% of all cases of infantile nephrotic syndrome (onset at 3-12 months). 25 In another study restricted to children with the pathologic findings of diffuse mesangial sclerosis alone, mutations in PLCE1 were found to be responsible for >25% of all cases of nephrotic syndrome. 26 As with many other genetic conditions, most autosomal recessive forms of nephrotic syndrome typically have onset in childhood, are highly penetrant, and are likely to be associated with other malformations.
By contrast, the major genetic causes of autosomal dominant forms of nephrotic syndrome include mutations in inverted formin 2 (INF2), short transient receptor potential channel 6 (TRPC6), Wilms tumor protein (WT1) and alpha-actinin-4 (ACTN4) (Box 1). Three different studies reported that mutations in INF2 are probably responsible for about 16% of all cases of autosomal dominant nephrotic syndrome related to FSGS in a predominantly adult population. 15, 27, 28 Unlike autosomal recessive disease, autosomal dominant forms of nephrotic syndrome typically have their onset during adulthood, are incompletely penetrant, and may even be asymptomatic. Now that high-throughput genomic techniques are available, genetic risk factors for FSGS and complex inheritance patterns of FSGS caused by gene-gene or gene-environment interactions are now being reported. 29, 30 For example, variants in MYH9 and APOL1 were recently reported as risk factors for nephrotic syndrome with pathological features of FSGS in African Americans. 29, 30 At present, no population-based data exist to clarify the overall disease burden caused by single gene defect forms of nephrotic syndrome. However, the overall consensus is that these forms probably represent only a tiny fraction of all cases of nephrotic syndrome, with the large majority of cases being idiopathic.
The prevalence of single gene defects also varies with age and, in some cases, with ethnicity. In a study of familial cases of nephrotic syndrome, 85% of cases of congenital nephrotic syndrome (onset in the first 3 months of life) and 44% of cases of infantile-onset nephrotic syndrome (onset at 3-12 months) were caused by mutations in one of four genes-specifically NPHS1, NPHS2, WT1 and LAMB2. 25 In our collective experience, even among cases of obvious familial nephrotic syndrome the cause remains unknown in about 80% of cases. A negative result on candidate gene screening does not, therefore, exclude hereditary disease. The primary aims of genetic testing are to establish a diagnosis in symptomatic individuals, and to predict risk in family members. Standardized criteria for genetic testing in both children and adults who present with nephrotic syndrome are clearly needed.
Is routine testing justified?
The use of genetic testing should be considered in a similar way to the use of any other diagnostic test. Before ordering a test, the clinician should address three pertinent questions. Firstly, is the result of this test likely to aid in diagnosis? Secondly, is the test result likely to alter the manage ment of the patient or better inform a discussion of likely outcomes and prog nosis? And thirdly, is the test result from the proband likely to produce data on risk in other family members? We believe that the answer to at least one of these three questions should be "yes" before genetic testing is ordered in a patient with nephrotic syndrome. As already discussed, <2% of currently available genetic tests for nephrotic syndrome are likely to identify a disease-causing mutation, raising the important question of cost versus benefit. In addition, a negative test does not exclude a diagnosis of monogenic nephrotic syndrome, as hereditary nephrotic syndrome and FSGS are profoundly heterogeneous, and additional genes are almost certainly yet to be found. Based on these concepts, we do not currently recommend universal genetic testing, but we do fully support testing in subsets of patients with nephrotic syndrome in whom actionable findings are likely. In a recent study of a Spanish cohort of patients with paediatric or adult-onset nephrotic syndrome, Santín et al. found that a family history of nephrotic syndrome and early-onset disease were the most important risk factors for the presence of pathogenic mutations in known genes implicated in nephrotic syndrome. 31 Based on the epidemiologic data we have presented and our own personal experience, we recommend genetic testing for the following categories of patients: children presenting with congenital nephrotic syndrome (onset in the first 3 months of life), children presenting with infantile nephrotic syndrome (onset from 3-12 months) patients in whom nephrotic syndrome is part of other malformations or syndromes, and all patients with a family history of nephrotic syndrome or chronic kidney disease (Box 2).
We propose that the algorithm shown in Figure 1 should be used to determine which patients with nephrotic syndrome should undergo genetic testing, and which specific tests should be ordered. Although genetic testing will add to the overall cost of the management of a patient with nephrotic syndrome, it is still less expensive than the cost of managing chronic kidney disease. The advantages of genetic testing should not only be viewed from the point of view of therapeutic intervention. Other advantages include improved information for patients and families on the likely clinical course of disease, information that could improve the selection of appropriate transplant donors, and the potential for providing genetic counselling for other family members.
Methods of testing
The availability of rapid and cost-effective genetic tests should not be seen as a replacement for the detailed and meticulous clinical evaluation of patients. Instead, obtaining a thoughtful family history and constructing pedigrees within the limited time available during consultation should be viewed as a challenge, and will help in stream lining the choice of tests for the patient. In the USA, most commercial laboratories (those conforming to the regulatory standards of the Clinical Laboratory Improvement Amendments [CLIA]) use exon primers to identify mutations in panels of candidate genes for specific disorders. This approach is based on the fact that single gene defects identified to date have invariably been in the coding regions of the gene of interest. The advantages of such an approach are that results can be returned to patients relatively quickly and that the interpretation of positive results does not require robust bioinformatics support. The interpretation of negative results, however, is more problematic, as the patient may either have a mutation in noncoding regions of candidate genes or they may have mutations in novel genes.
The rapid technological advances in 'next generation sequencing' will likely decrease the use of the candidate gene approach and may replace it as the test of choice in the near future. With this method, either the whole genome (that is, the total genome), or the coding regions of all the genes in the human genome (that is, the whole exome) are sequenced. The major advantages of this method are that the yield of positive results is likely to be higher because the test is not limited to known candidate genes, and that mutations may be identified in previously unrecognized novel genes. The discovery of novel genes will not only aid in diagnosis, but also have the potential to improve our understanding of the molecular mechanisms of disease in nephrotic syndrome and to provide potential molecular drug targets for therapy. At present, whole-exome sequencing in genetic diagnosis is only used in research laboratories; the enormous amount of data generated with this method requires complex and well-organized bioinformatics support for analysis. In addition, whole-exome sequencing may identify deleterious variants that are immaterial to the disease being investigated. Most individuals have multiple 'deleterious' mutations in their genome that do not seem to cause morbidity or mortality. 32 Such technical advances highlight the urgent need for the development of clinical care guidelines offering accurate, ethical and concise approaches for communicating incidental but potentially actionable findings to affected patients and families during the confined timeframes of clinic visits.
Clinical use of genetic testing
Availability One of the most important early challenges for clinicians caring for patients with nephrotic syndrome is to determine which genetic tests for nephrotic syndrome are currently available. Fortunately, an outstanding free online resource provides updated information about the availability of genetic testing for a vast array of genetic diseases, including nephrotic syndrome. 33 The website is sponsored by the National Center for Biotechnology Information and it enables users to search for information using relevant criteria, including the disease, gene, protein, laboratory performing the test, or laboratory director.
Insurance coverage
In many countries, insurance coverage for genetic testing in nephrotic syndrome remains another important clinical challenge. Not all insurers currently
Box 1 | Most prevalent NS genes

Autosomal recessive genes
Abbreviation: NS, nephrotic syndrome. reimburse for genetic testing in patients with nephrotic syndrome, since this procedure is not yet considered the 'standard of care' . In the USA, insurers may not reimburse 'research' or 'experimental' patient costs, or compensate for tests from non-CLIA-approved research laboratories. Unfortunately, the lack of insurance coverage makes genetic testing for nephrotic syndrome financially prohibitive for many families worldwide.
Box 2 | Indications for genetic testing in NS
Treatment following a positive test
Studies have shown undisputable evidence that the majority of cases of hereditary and familial nephrotic syndrome caused by single gene defects are steroid resistant. The largest series so far are two studies by the Hildebrandt group in the USA. These series showed that virtually all cases of nephrotic syndrome caused by NPHS2 mutations were steroid resistant, and that mutations in NPHS2 were rare in a cohort of children with SSNS. 23, 34 Furthermore, a German study showed that all patients with monogenic nephrotic syndrome were steroid resistant (irrespective of their genetic mutation) and that none of these patients achieved complete remission with ciclosporin A; only a partial response occurred in a small percentage of these patients. 35 Anecdotal reports in the literature, however, have shown that individuals with nephrotic syndrome caused by genetic mutations may be responsive to immunomodulatory or chemo therapeutic agents. 12, 36, 37 Moreover, in addition to their immunosuppressive properties, some agents now used for the treatment of nephrotic syndrome may affect the podocyte actin cytoskeleton. 38, 39 One study showed that in addition to its effect on the immune system, ciclosporin may exert antiproteinuric effects by blocking the calcineurin-mediated dephosphorylation of synaptopodin, leading to stabilization of the actin cytoskeleton (which is often disrupted in cases of familial nephrotic syndrome). 38 Since a direct relationship exists between clinical response to therapy and risk of progression to ESRD in patients with monogenic nephrotic syndrome, and considering the devastating impact of ESRD on a growing child or adult, treatment decisions need to be pragmatic. In our opinion, confirmation of a positive genetic test should be followed by a detailed unbiased discussion with the patient and/or the family. They should be advised that the chance of a clinical response to therapy is lower in monogenic nephrotic syndrome than in nongenetic diseases, and that currently available therapies are often associated with considerable adverse effects. The patient and/or the family should also be informed, however, that response to therapy, even if it is only a partial response, could prevent or slow the progression to ESRD requiring dialysis and transplantation. Having provided these key details, the physician should support the patient and/or the family in the decision-making process. For clinicians, the knowledge that the patient has a genetic mutation should help in modifying the intensity and duration of immunosuppression, considering the systemic and renal toxicity of most of these agents. For example, with this knowledge a clinician may consider stopping therapy if no response (partial or complete remission) is observed within 6 weeks of starting therapy. Irrespective of the results of genetic testing, the use of angiotensinconverting-enzyme inhibitors and lipidlowering agents that are known to slow the rate of progression of glomerular diseases should also be included as part of the standard supportive care for all patients with SRNS, including those with genetic forms of nephrotic syndrome. [40] [41] [42] [43] [44] Testing and kidney transplantation Several studies have shown that individuals with nephrotic syndrome related to FSGS caused by single gene defects have a reduced risk of recurrence of FSGS in the kidney allograft if they undergo renal transplantation. 23, [45] [46] [47] In a recent survey of children with FSGS who received at least one kidney transplant, Jungraithmayr et al. reported a recurrence rate of 36%. 47 Of note, 11 of these patients had FSGS caused by NPHS2 mutations and none of these patients had recurrence of disease.
The reason for the low rate of recurrence of disease in patients with genetic FSGS who undergo renal transplantation suggests that this disease is a kidney-specific one (unlike idiopathic FSGS, which frequently recurs after transplantation). It should also be noted that the risk of recurrence is different for different gene defects, and that exposure to new antigens from the donated kidney may lead to the development of de novo immune-complex disease. 48 Indeed, a small percentage of individuals with nephrotic syndrome caused by nephrin mutations develop heavy proteinuria after transplantation and have circulating antinephrin antibodies. 48 Together, these data support the use of pretransplantation genetic testing in patients with nephrotic syndrome. Such testing will provide clinicians with information that might be helpful in predicting the post-transplantation course, and in guiding post-transplantation management.
A much more controversial issue is the utility of genetic testing in kidney donors. We do not recommend routine genetic testing for single gene defects in kidney donors because of the low incidence of these mutations in the general population. However, careful thought is required prior to embarking on living-related donor (LRD) kidney transplantation from family members of patients with known single gene defects. The risk obviously differs between autosomal dominant and auto somal recessive conditions. Theoretically, in autosomal recessive disease, an unaffected individual with a heterozygous change would not be expected to develop disease, although the risk of developing kidney disease as a result of unknown modifier genes and/or environmental factors is not clear. The situation is even more problematic in autosomal dominant disease, where a mutation may be incompletely penetrant, and affected individuals may develop disease later in life or even remain asymptomatic throughout their life.
Our group previously reported on donors who developed FSGS and ESRD years after donating kidneys to affected siblings or other family members with familial FSGS. 49 In one of the families, we identified the disease-causing mutation and found that the recipient, the donor and other affected members of the family carried the same mutation, confirming that this mutation was the cause of the disease in this family (unpublished observation). These observations emphasize the importance of obtaining a complete family history prior to LRD kidney donation and lend support to the use of genetic testing in living-related donors of individuals with genetic forms of nephrotic syndrome. We do not support the use of LRD donation from families with known hereditary disease and unknown gene defects. If the gene defect is known, LRD kidneys should only be accepted if certified testing of donors has been performed to ensure that they do not have the mutation.
Genetic testing in clinical trials
Historically, genetic testing for nephrotic syndrome has not been performed as a standard investigation in clinical trials owing to the fact that the tests were not routinely available. Now that some tests are widely available, however, clinical trials in nephrotic syndrome have begun to incorporate genetic testing-typically for NPHS2 and WT1-at entry into their protocols. Although therapeutic selection during trials in nephrotic syndrome has not yet been driven by these genetic findings, it is likely that in the near future these results will be used to directly compare treatment responses for various selected homozygous and heterozygous mutations. We believe that patients with monogenic nephrotic syndrome should not be excluded from clinical trials, since data regarding treatment responses in this patient group are limited (with the exception of a wellestablished management algorithm in congenital nephrotic syndrome). However, criteria for the withdrawal of individuals with monogenic nephrotic syndrome once they are enrolled should be strict, in order to mitigate the potential systemic toxicity of trial drugs and agents.
Conclusions
In conclusion, advances in molecular genetics and genomic science have opened the door to dramatically improving our understanding of the molecular basis of nephrotic syndrome and enabled the precise diag nosis of disease. However, these advances now pose notable challenges in terms of their clinical utility for both clinicians and for patients and families. Despite these challenges, the advances in genetic diagnosis have created an unprecedented opportunity to develop a 'personalized' approach to provide improved care for both children and adults with nephrotic syndrome.
